BidaskClub lowered shares of C.R. Bard, Inc. (NYSE:BCR) from a hold rating to a sell rating in a research report report published on Saturday, August 5th.
Other research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of C.R. Bard from a hold rating to a buy rating and set a $351.00 price target for the company in a research report on Tuesday, June 6th. BMO Capital Markets reissued a buy rating and set a $255.00 price target on shares of C.R. Bard in a research report on Tuesday, April 11th. Morgan Stanley cut shares of C.R. Bard from an overweight rating to an equal weight rating in a research report on Monday, April 24th. Finally, Jefferies Group LLC lifted their price target on shares of C.R. Bard from $237.00 to $317.00 and gave the company a hold rating in a research report on Monday, April 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. C.R. Bard has an average rating of Hold and a consensus price target of $285.67.
Shares of C.R. Bard (BCR) traded down 0.30% during trading on Friday, hitting $318.20. 431,723 shares of the stock traded hands. C.R. Bard has a 12 month low of $203.63 and a 12 month high of $323.27. The company has a 50 day moving average price of $319.58 and a 200 day moving average price of $286.55. The firm has a market cap of $23.12 billion, a price-to-earnings ratio of 41.77 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same quarter in the previous year, the firm posted $2.54 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts anticipate that C.R. Bard will post $11.82 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is 13.67%.
In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of BCR. Fundsmith LLP raised its position in C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock worth $633,996,000 after buying an additional 52,272 shares during the last quarter. Creative Planning raised its position in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares during the last quarter. Granite Investment Advisors LLC raised its position in C.R. Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock worth $8,270,000 after buying an additional 4,159 shares during the last quarter. Buffington Mohr McNeal raised its position in C.R. Bard by 14.1% in the first quarter. Buffington Mohr McNeal now owns 7,545 shares of the medical instruments supplier’s stock worth $1,875,000 after buying an additional 930 shares during the last quarter. Finally, Huntington National Bank raised its position in C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock worth $4,079,000 after buying an additional 1,278 shares during the last quarter. Institutional investors and hedge funds own 77.14% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.